Trial Profile
A Phase II, Single-Arm, Open-Label Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab emtansine (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors Genentech
- 07 Jan 2020 Results of an individual patient-level data pooled analysis of trials testing T-DM1 in the advanced setting investigating T-DM1-induced cardiotoxicity, with a focus on the incidence of CEs, clinical presentation of CEs, impact on treatment continuity, reversibility as well as in any potential risk factors that could aid in patient selection and follow-up published in the European Journal of Cancer
- 22 Dec 2011 Actual patient number is 110 according to ClinicalTrials.gov.
- 22 Dec 2011 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.